Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs
(1999; 61 pages) [French] [Spanish] View the PDF document
Abstract
These guidelines respond to the WHA requests: They are aimed to provide guidance to Member States in developing their own national measures to combat counterfeiting of drugs. The guidelines provide an overview of the problem and factors contributing to the counterfeiting of drugs. They outline also the steps to be followed in developing national strategies as well the specific measures to be considered in combating counterfeit drugs. Issues such as, approaches to country studies, inspection of suspected counterfeit drugs, screening of potentially counterfeit products and training of human resources are also dealt with in the guidelines.
Table of Contents
View the documentExecutive Summary
Open this folder and view contents1. Introduction
View the document2. Overview of the problem
View the document3. Impact on public health
View the document4. Factors facilitating counterfeiting
Open this folder and view contents5. Developing national strategies
Open this folder and view contents6. Specific measures
Open this folder and view contents7. Assessment of the problem at the national level
Open this folder and view contents8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
Open this folder and view contents9. Test methods
Open this folder and view contents10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
View the document11. Conclusion
View the documentReferences
View the documentSelected further reading
View the documentAcknowledgements
View the documentGlossary
 

Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs

Guidelines for the development
of measures to combat
counterfeit drugs

Department of Essential Drugs and
Other Medicines
World Health Organization
Geneva, Switzerland

ORGANISATION MONDIALE DE LA SANTE

WHO/EDM/QSM/99.1
DISTR: GENERAL
ORIGINAL: ENGLISH

This document has been prepared under the auspices of the DMP-DAP Joint Project on Counterfeit Drugs which was administered by the World Health Organization Division of Drug Management and Policies (DMP) and the Action Programme on Essential Drugs (DAP) from 1995 to 1997. With effect from January 1999, the Department of Essential Drugs and Other Medicines Department (EDM) includes the former DAP and most components of DMP.

©World Health Organization (1999)

This document is not a formal publication of the World Health Organization (WHO) and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced, translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The view expressed in documents by named authors are solely the responsibility of those authors.

 

to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014